Anticancer Activities of Newly Synthesized Chiral Macrocyclic Heptapeptide Candidates
Mohamed H. Abo-Ghalia,
Gaber O. Moustafa,
Abd El-Galil E. Amr,
Ahmed M. Naglah,
Elsayed A. Elsayed,
Ahmed H. Bakheit
Affiliations
Mohamed H. Abo-Ghalia
Department of Peptide Chemistry, National Research Centre, Dokki 12622, Cairo, Egypt
Gaber O. Moustafa
Department of Peptide Chemistry, National Research Centre, Dokki 12622, Cairo, Egypt
Abd El-Galil E. Amr
Pharmaceutical Chemistry Department, Drug Exploration & Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
Ahmed M. Naglah
Department of Peptide Chemistry, National Research Centre, Dokki 12622, Cairo, Egypt
Elsayed A. Elsayed
Bioproducts Research Chair, Zoology Department, Faculty of Science, King Saud University, Riyadh 11451, Saudi Arabia
Ahmed H. Bakheit
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia
As important cancer therapeutic agents, macrocyclic peptides have recently drawn great attention, mainly because they are synthetically accessible and have lower toxicity towards normal cells. In the present work, we synthesized newly macrocyclic pyridoheptapeptide derivatives. The synthesized derivatives were characterized using standard chemical and spectroscopic analytical techniques, and their anticancer activities against human breast and hepatocellular cancer cells were investigated. Results showed that compounds 1a and 1b were the most effective against hepatocellular (HepG2) and breast (MCF-7) cancer cell lines, respectively.
